LUNG CANCER

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses PD-1 and PD-L1 in various cancers.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, UCLA, describes the development of cyclin-dependent kinases (CDKs) for the treatment of cancer.

Researchers at the NCI have developed the most comprehensive analysis of coding variants in the most frequently studied human tumor cell lines in cancer research.

The FDA has approved the pan-HER inhibitor afatinib (Gilotrif), along with a companion diagnostic, to treat patients with metastatic NSCLC who express specific types of EGFR mutations.

Suresh S. Ramalingam, MD, from the Winship Cancer Institute, discusses the investigation of the heat shock protein 90 inhibitor ganetespib as a treatment for patients with advanced lung cancer.

The next-generation PI3 kinase (PI3K) inhibitor GDC-0032 has shown signs of efficacy in patients with advanced cancers that were mutated for the PI3K alpha gene.

The second-generation TKI dacomitinib, designed to treat NSCLC, is being evaluated in a clinical trial that will measure the drug’s effectiveness as a first-line treatment.

Alice T. Shaw, MD, PhD, describes a trial comparing crizotinib and chemotherapy in patients with advanced ALK-positive non-small cell lung cancer.

Roy S. Herbst, MD, PhD, comments on the emergence of immunotherapies for multiple types of cancer including MPDL3280A for non-small cell lung cancer.

Crizotinib demonstrated superiority to chemotherapy for the treatment of previously treated, advanced non-small cell lung cancer (NSCLC) with ALK rearrangement in a trial published online by The New England Journal of Medicine.